Oncotarget

Research Papers:

Thrombin induced platelet-fibrin clot strength in relation to platelet volume indices and inflammatory markers in patients with coronary artery disease

Hai-Chen Lv, Hong-Yi Wu, Jia-Sheng Yin and Jun-Bo Ge _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:64217-64223. https://doi.org/10.18632/oncotarget.19450

Metrics: PDF 1386 views  |   HTML 1984 views  |   ?  


Abstract

Hai-Chen Lv1,*, Hong-Yi Wu2,*, Jia-Sheng Yin2 and Jun-Bo Ge2

1Department of Cardiology, First Affiliated Hospital of Dalian Medical University, Dalian, China

2Shanghai Institute of Cardiovascular Diseases, Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai, China

*These authors have contributed equally to this work

Correspondence to:

Jun-Bo Ge, email: [email protected]

Keywords: coronary artery disease, thrombelastography, inflammatory marker, platelet volume index, platelet activation

Received: January 02, 2017     Accepted: April 11, 2017     Published: July 22, 2017

ABSTRACT

Platelet aggregation and inflammation are both implicated in coronary artery disease (CAD). Thrombin induced platelet-fibrin clot strength (MAThrombin) measured by thrombelastography (TEG) has been proved to be a novel marker of platelet aggregation. The aim of this study was to investigate the correlation of MAThrombin to platelet volume indices (PVIs) or to inflammatory markers in different types of CAD. 206 patients with different types of CAD were enrolled. MAThrombin, PVIs, including mean platelet volume (MPV), platelet distribution width (PDW), and platelet-large cell ratio (P-LCR) as well as inflammatory markers, including high-sensitivity C-reactive protein (hs-CRP) and fibrinogen (Fbg) were measured. Multiple linear regression models were used to analyze the association between MAThrombin, PVIs, and inflammatory markers. MAThrombin and inflammatory markers both varied with CAD types (P<0.001). MAThrombin was correlated to PVIs in NSTEMI individuals (MPV, r=0.393, P=0.007; PDW, r=0.334, P=0.023; P-LCR, r=0.382, P=0.008), but had inner-link with inflammatory markers in STEMI cases (hs-CRP, r=0.499, P<0.001; Fbg, r=0.500, P<0.001). These findings may suggest different mechanisms of platelet aggregation in different types of CAD. Moreover, MAThrombin may be used as a potential parameter to evaluate platelet aggregation and inflammation together.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 19450